AFC
TEVA icon

AFT Forsyth & Company’s Teva Pharmaceuticals TEVA Stock Holding History

AFT Forsyth & Company’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		$5K Hold
135
– – 0.01% 292
2013
Q2 		$5K Buy
+135
New +$5.26K 0.01% 275

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

AFT Forsyth & Company's TEVA Position: Q3 2013 in Review

AFT Forsyth & Company held its Teva Pharmaceuticals (TEVA) position steady in Q3 2013 at 135 shares worth $5K. The position accounts for 0.01% of the portfolio, ranked #292.

AFT Forsyth & Company first reported a position in TEVA in Q2 2013 and has held it in 2 quarters since. 705 funds tracked by Wall St. Rank hold TEVA as of Q3 2013.

  • AFT Forsyth & Company held 135 shares of Teva Pharmaceuticals worth $5K as of Q3 2013.
  • AFT Forsyth & Company left its Teva Pharmaceuticals share count unchanged in Q3 2013.
  • Teva Pharmaceuticals made up 0.01% of AFT Forsyth & Company's portfolio in Q3 2013, its #292 holding.
  • AFT Forsyth & Company first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 2 quarters since.
  • 705 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2013.

Based on AFT Forsyth & Company's 13F filing for Q3 2013, filed 8 Nov 2013.